Skip to main content

Table 3 Regression outcomes of associations

From: Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey

 

Outcome: increase in take-home doses

Outcome: decrease in in-person counseling requirement

Univariate association OR [95%CI]

Controlled for methadone treatment length OR [95%CI]

Univariate association OR [95%CI]

Controlled for methadone treatment length OR [95%CI]

Age

30–39 vs < 30

0.97 [0.56, 1.67]

0.84 [0.47, 1.50]

1.62 [0.85, 3.04]

1.52 [0.78, 2.93]

40–49 vs < 30

0.74 [0.39, 1.40]

0.63 [0.31, 1.24]

0.89 [0.44, 1.80]

0.81 [0.38, 1.70]

50 + vs < 30

1.58 [0.68, 3.77]

1.28 [0.51, 3.31]

0.82 [0.33, 2.10]

0.79 [0.29, 2.21]

Gender

Female vs Male

1.35 [0.79, 2.35]

1.35 [0.78, 2.35]

0.82 [0.41, 1.53]

0.82 [0.41, 1.55]

Other vs Male

1.01 [0.36, 2.76]

0.99 [0.35, 2.74]

0.54 [0.18, 1.65]

0.53 [0.18, 1.62]

Cost

20 – 99$ vs < 20$

0.57 [0.17, 1.75]

0.50 [0.15, 1.58]

1.34 [0.34, 8.84]

1.25 [0.32, 8.30]

100 – 199$ vs < 20$

0.73 [0.32, 1.62]

0.60 [0.25, 1.37]

0.23 [0.10, 0.52]

0.20 [0.08, 0.46]

 > 200$ vs < 20$

0.85 [0.52, 1.39]

0.78 [0.47, 1.28]

0.55 [0.32, 0.95]

0.51 [0.29, 0.89]

Region

Northeast vs Midwest

1.31 [0.72, 2.37]

1.31 [0.72, 2.39]

2.61 [1.22, 5.84]

2.54 [1.18, 5.70]

South vs Midwest

1.24 [0.72, 2.14]

1.27 [0.74, 2.19]

0.92 [0.50, 1.65]

0.94 [0.51, 1.70]

West vs Midwest

0.61 [0.25, 1.41]

0.64 [0.26, 1.49]

0.71 [0.29, 1.80]

0.71 [0.29 1.83]

Length on methadone treatment

1–5 years vs < 1 year

1.51 [0.73, 3.19]

–

1.07 [0.45, 2.37]

–

5–10 years vs < 1 year

1.57 [0.74, 3.41]

–

1.30 [0.53, 3.04]

–

 > 10 years vs < 1 year

2.01 [0.93, 4.41]

–

1.16 [0.47, 2.73]

–